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Screening for asymptomatic 
rheumatic heart disease: 
Understanding the mechanisms 
key to the diagnostic criteria
vular changes that characterise more chronic rheumatic cardiac 
involvement outside that of the acute episodes.(17-19) Marijon, et 
al. exposed the lack of sensitivity and specificity of these criteria, 
during screening for subclinical disease, by adding important 
morphological criteria of chronic rheumatic valve involvement 
and degrading the importance of differentiating functional 
from pathological valvular regurgitation, although not removing 
this functional requirement completely (Marijon Combined 
Criteria).(19) The modified WHO criteria, and new WHF criteria, 
are broadly similar in terms of requiring both a significant 
functional and morphological deficit in order to make a definite 
diagnosis of RHD echocardiographically when dealing with 
the most common lesion, mitral regurgitation.(16,20) The WHF 
criteria have raised the bar in terms of diagnostic requirements 
for RHD with the aim of improving specificity of these criteria. 
Concern has however now been raised that this is increasing 
specificity at the expense of sensitivity which is particularly 
problematic from a screening perspective.(14,21) Further concerns 
relate to the complexity of these criteria as screening criteria to 
be used in the field by moderately skilled personnel. This is an 
important goal if population based screening is to be imple-
mented on a large scale (Table A). It remains very difficult, even 
for experienced echocardiography operators, to differentiate 
some cases of mild rheumatic cardiac involvement from the 
normal spectrum or alternative pathologies. This complexity, as 
well as differences in the application of the guidelines, technical 
echocardiography pitfalls and fundamental concerns about 
some of the screening criteria and methodology all have the 
potential to lead to non-uniformity in assessment and degra-
dation of screening accuracy. This must be kept in mind 
when comparing different studies, even if identical criteria have 
been used.
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The burden of rheumatic heart disease (RHD) remains 
unacceptably high in the third world, including Sub-Saharan 
Africa.(1-4) Screening for asymptomatic RHD (with a view to 
instituting secondary prophylaxis in affected cases) has received 
much press and is being actively studied as a potential strategy 
for tackling the RHD problem. This strategy relies entirely on 
case detection and echocardiography has been identified as 
a superior modality (compared to clinical screening with 
auscultation) to deliver these cases.(5-15) However, this strategy 
has its problems. This focused review will critically evaluate the 
shortcomings of the current criteria used for the screening of 
asymptomatic RHD. The review provides an in depth look at 
the mechanisms underpinning these shortcomings in order to 
find potential solutions.
Significant variation in the criteria used in the echocardio-
graphic screening studies quoted above has made it difficult 
to compare studies directly. In an effort to address this, the 
World Heart Federation (WHF) published a set of guidelines 
that has been widely adopted as the diagnostic criteria of 
choice for diagnosing subclinical or asymptomatic RHD.(16) 
The WHF criteria are a marked improvement on the original 
WHO Doppler based criteria for specificity. The latter were 
derived from criteria designed to diagnose acute rheumatic 
carditis during episodes of acute rheumatic fever (ARF) by 
differentiating functional (normal spectrum) from pathological 
regurgitation. This understandably ignored morphological val-
This focussed review describes important problems 
experienced in the world of echocardiographic screening 
for asymptomatic rheumatic heart disease (RHD). It 
offers a critical appraisal of the screening criteria and 
their application and explores some of the fundamental 
principles underpinning the shortcomings of individual 
criteria. The author illustrates important mechanisms 
that underlie the morphological changes seen in RHD 
that must be accounted for if these criteria are to be 


















The WHF criteria broadly classify rheumatic involvement into 
“definite RHD” and “borderline RHD” categories. In principle, 
for the majority of cases, they rely on the identification of both 
significant morphological and functional deficits, typical of 
rheumatic involvement, to diagnose a case as “definite RHD”. 
Cases with either a typical morphological or functional abnor-
mality (principally regurgitation in the asymptomatic screening 
population), but not both, are designated “borderline RHD”. 
It is not difficult to predict that this latter group could be large 
and diverse and include cases varying from the normal spectrum 
to those that undoubtedly have RHD. The reason for this is 
partly due to the fact that the main form of valvular dysfunction 
seen, mitral regurgitation (MR), is quite non-specific and occurs 
secondary to a variety of pathologies. Seen in its mild form it is 
commonly identified as part of the normal spectrum. Moreover, 
differentiation of true pathological from functional (normal 
spectrum) regurgitation is not as simple as measuring a jet 
length and attributing excess length to RHD. It is important to 
consider the potential mechanisms at play. Valvular clefts, 
milder forms of myxomatous degeneration and small fenes-
trations are potential alternative causes that need to be 
considered on the pathology side of the spectrum. In addition, 
it is now becoming clear to us that normal (non-rheumatic) 
spectrum valves that leak through prominent posterior leaflet 
inter-scallop separations/clefts (part of the normal spectrum of 
mitral valves) can cause regurgitation in the pathological range, 
as judged by the WHF criteria. This muddies the waters of 
functional versus pathological regurgitation assessment and 
underscores the importance of identifying the mechanistic 
cause of regurgitation in every case of regurgitation, whether 
pathological (but mild) or not. Identifying whether the regur-
gitation you have identified has a normal spectrum variant 
morphological counterpart that can be demonstrated on the 
echocardiogram to be the cause of the MR goes a long way to 
reducing the bulk of normal cases that land up in the “borderline” 
bin. This highlights the danger of divorcing valve dysfunction 
from a mechanistic cause based on morphology and leaflet 
motion and illustrates one of the problems related to weighting 
the functional assessment too heavily in the criteria. The other 
side of this coin is that a heavy handed reliance on a functional 
valvular deficit leaves cases of isolated, but typical, morphol-
ogical valve changes of RHD, stuck in this “borderline RHD” 
group. This would appear to protect specificity in some 
instances, but at the cost of sensitivity. Getting the balance 
right will require reassessment of the main elements of the 
current diagnostic criteria.
FUNCTIONAL EVALUATION FOR RHD: FOCUS 
ON REGURGITATION EVALUATION
The principle that pathological MR identified during screening 
in a high prevalence area for RHD, is more likely to represent 
RHD, is a well-accepted one and is the departure point for the 
next discussion. Whether the presence of MR adds funda-
mentally to the diagnosis of RHD, or is useful in screening 
because it alerts the screener of a potential valve problem that 
might turn out to be RHD, is another question altogether.
TABLE A:  Screening criteria for asymptomatic RHD
A: World Heart Federation (WHF) Guideline 2012 for 
echocardiographic diagnosis of Rheumatic heart disease 
(RHD) in individuals younger than 20 years, abridged(16)
Diagnostic requirements for Defi nite RHD (either A, B, C, or D)
A:  Pathological MR and at least 2 morphological features of RHD of 
the MV
B: MS mean gradient ≥4mmHg
C:  Pathological AR and at least 2 morphological features of RHD of 
the AV
D: Borderline disease of both the AV and MV
Diagnostic requirements for Borderline RHD (either A, B, or C)
A:  At least 2 morphological features of RHD of the MV without 
pathological MR or MS
B: Pathological MR
C: Pathological AR
B: WHF guideline 2012: Echocardiographic criteria for 
pathological regurgitation
Diagnostic requirements for pathological mitral regurgitation (MR)
(All 4 Doppler echocardiographic criteria must be met)
•  Seen in 2 views
•  In at least 1 view, jet length ≥2cm
•  Velocity ≥3m/s for 1 complete envelope
•  Pan-systolic jet in at least 1 envelope
Diagnostic requirements for pathological aortic regurgitation (AR)
(All 4 Doppler echocardiographic criteria must be met)
•  Seen in 2 views
•  In at least 1 view, jet length ≥1cm
•  Velocity ≥3m/s in early diastole
•  Pan-diastolic jet in at least one envelope
C: WHF Guideline 2012: Morphological features of RHD 
on echocardiography
Features in the MV
•   AMVL thickening ≥3mm (≥4mm if aged over 20yrs, ≥5mm if aged 
over 40yrs)
•  Chordal thickening
•  Restricted leafl et motion
•  Excessive leafl et tip motion during systole
Features in the AV
•  Irregular or focal thickening
•  Coaptation defect
•  Restricted leafl et motion
•  Prolapse
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SCREENING FOR RHEUMATIC HEART DISEASE
Despite the well known technical pitfalls of assessing regurgitant 
jets with colour Doppler, including the importance of colour 
scale settings, jet length measurement represents a very 
reasonable start to the assessment of regurgitation significance. 
The majority of guidelines on severity assessment of patients 
with moderate or more MR and AR (Aortic Regurgitation) 
have removed jet length assessment from suggested quanti-
fication assessment. However, the context here is different and 
relates to the assessment of mild, or very mild, MR. Guideline 
quantification focuses on, and performs best at differentiating 
moderate from severe MR but has a smaller role to play with 
milder degrees of MR. MR jet length assessment is simple and 
reasonably reproducible. The question asked here is whether 
this is more MR than expected in the normal population. The 
jet length requirement of >2cm seems to fare reasonably well 
in isolation, although the validation of this against a set of criteria 
requiring MR as part of the criteria is of course inherently 
flawed.(14,22) In addition, as one would predict, it has been shown 
to miss a number of cases with isolated morphological defects 
in a screening context.(14) The increase of jet length, from the 
1cm used in previous guidelines to the 2cm (for MR) cut-off 
used in the WHF, appears to have addressed specificity 
problems quite well and in this context the question really is 
what added value any additional Doppler criteria offer to a 
simple colour flow assessment.
The requirement that a regurgitant jet should be visible in 2 
different views tests nothing else than the operator’s ability to 
visualise where the jet is originating from, and to section that 
plane in another view. This should always be achievable, even if 
it requires dynamic scanning, and this per se should say nothing 
about whether the MR is pathological or physiological. It could 
even be argued that eccentric or commissural jets, which are 
not central but probably have a higher likelihood of being 
pathological or related to RHD, are less likely to fulfil this 
requirement as they are less likely to be sectioned in the 
standard echo planes. This criterion is in serious need of 
retirement. 
The requirement that an MR jet should achieve a maximum 
MR jet velocity of >3m/s to rule in for pathological MR again 
makes little sense. The MR jet velocity represents the instan-
taneous pressure difference between the left ventricle (LV) 
and left atrium (LA) and unlike CW jet density is not a measure 
of regurgitation severity. Very broadly speaking, the pressure 
difference between the systemic LV and low pressure LA is 
often in the range of 100mmHg (e.g. 110mmHg LV systolic 
pressure in a normotensive individual) – 10mmHg (normal LA 
pressure in an individual with low filling pressures). This would 
equate to an MR jet velocity of 5m/s via the simple Bernoulli 
equation (ΔP = 4V2). This velocity should not reasonably be 
expected to be below 3m/s (36mmHg) in anyone with an 
intact circulation. The argument here is undoubtedly that an 
incomplete MR CW Doppler envelope, related to milder 
degrees of regurgitation, is likely to have a lower velocity 
because the envelope is incomplete. If this is in fact the 
argument, the criterion can simply be restated to require a 
complete Doppler envelope to be present, a simple assessment 
to do. The misleading idea of a velocity assessment of 3m/s as 
a judgement of severity could then be abandoned. In addition, 
it represents duplication of the principle of assessment for an 
incomplete jet, which is better judged in other ways. Problems 
with Doppler jet alignment degrading Doppler jet velocities, 
irrespective of regurgitation severity, are sidestepped if the 
velocity focus of this criterion is removed. At the very least, 
abandoning this criterion would be an honest attempt to 
establish a logical mechanistic foundation for the assessment. In 
short, as it currently stands, it makes no logical sense. 
The last requirement is that a pathological MR jet should be 
pansystolic (and pandiastolic for AR). Here it is important to 
differentiate the jet that is not occurring throughout systole 
from the jet that is periodically moving out of the Doppler 
beam due to cardiac translation in systole (or diastole), the 
latter represents a technical problem and would not indicate a 
lesser degree of regurgitation. Late systolic MR may hint at the 
underlying mechanism due to prolapse spectrum disease, which 
remains the one useful aspect of this evaluation. This must then 
be evaluated specifically. Colour m-mode is a very useful 
modality to add in this context, as it can be used to accurately 
define the time course of regurgitation after the fact, during 
post processing. This may be relevant if the Doppler envelope 
suggests MR is not pansystolic, and yet this does not correlate 
FIGURE 1: Measuring AMVL thickness.
The double headed arrow indicates the direction of leaflet 
orientation. The thickness measurement is done perpendicular 
to this from edge-to-edge at the thickest area of the leaflet. 
A measurement of >3mm done with harmonics off would indicate 
a thickened AMVL and score a morphological criterion for RHD 



















with your visual assessment, essentially giving you a second 
chance to reassess this. It follows that, all else being equal, a 
pansystolic jet is likely to represent more severe degrees of MR 
when compared to a jet that occupies only part of the cardiac 
cycle. However, without a pathological mechanism demon-
strated to be responsible for the regurgitation, it actually adds 
little. Conversely, if an abnormal mechanism of regurgitation is 
present, the pansystolic nature of the jet is not required to 
make the diagnosis of abnormality. As noted though, the 
identification of late systolic MR, and the possible clue that this 
gives of a prolapse spectrum mechanism, remains informative.
MORPHOLOGICAL ASSESSMENT OF RHD
Leafl et thickness
The anterior mitral valve leaflet (AMVL) thickness is measured 
in the parasternal long axis view (PSLAX) towards the end of 
diastole with the MV maximally open and with the AMVL at 
maximal excursion. It is intuitive to imagine the leaflet taking 
on its thinnest configuration in this fully stretched out state, 
which supports assessing the leaflet thickness at this time in 
the cardiac cycle. In addition, it is suggested that the leaflet 
and chords are maximally separated at this point before a 
leaflet thickness measurement is done.(16) The AMVL thickness 
measurement is done as an edge-to-edge measurement 
(tissue blood interface to tissue blood interface) and 
perpendicular to the long axis of the leaflet at the point where 
the leaflet is deemed thickest (Figure 1). Another important 
stipulation is that the measurement be done with harmonics 
turned off (harmonic imaging will tend to cause blooming of 
leaflet tissue with an increase in the apparent leaflet thickness), 
an often noted omission when reviewing measurement 
technique (Figure 2).
The theoretical logic behind this methodology is sound as it 
firstly promotes accurate measurement of leaflet thickness by 
utilising axial resolution of ultrasound (when ultrasound hits 
the structure in question in a perpendicular fashion) in this view 
and timing in the cardiac cycle. Secondly, utilising this metho-
dology the measurement is done in the near field, which also 
maximises resolution, minimises edge smearing and therefore 
tends to minimise over-measuring of leaflet thickness (Figure 3). 
However, these positives have to be weighed against the 
downside of this technique, namely, difficulty in separating 
chords from leaflet when the AMVL is maximally open. The 
maximally open leaflet position promotes positioning of the 
chords on top of the ventricular aspect of the open MV leaflet. 
It can be difficult, or impossible, to achieve separation of chord 
and leaflet in this position. Over-measurement easily occurs at 
the tips of the AMVL where chords tend to implant and where 
leaflet–chord separation can be especially difficult to achieve. 
This is of course the area of the leaflet that often thickens first 
when affected by the rheumatic process and it is critical to 
ensure that subvalvular tissue is not included in the measurement. 
To measure the true leaflet thickness (free from chordal 
inclusion) might mean doing the measurement in a different 
view and at a different time point in the cardiac cycle which 
often leads to a remarkably smaller maximum thickness 
measurement (leaflet measures thinner) when compared to 
that achieved using the standard, recommended methodology. 
The realisation is often that the true leaflet was just not 
visualised separate from the chords (Figures 4, 5 and 6). 
FIGURE 2: Harmonic Imaging.
Harmonic imaging improves overall image quality and has become almost the default setting in general scanning practice. However, it can make 
structures look significantly thicker than they actually are due to the increase in echo pulse length. This becomes critical when making measurements 
of a very small magnitude such as with leaflet thickness measurements. The normal values given for leaflet thickness are based on measurements 
derived with harmonic imaging set to off. These PSLAX freeze frames at end diastole in the same patient illustrates the point.
Harmonics off Harmonics on
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FIGURE 3: Maximising Resolution.
In the PSLAX view (A) the maximally open MV places the AMVL in the ultrasound near-field and perpendicular to the ultrasound (US) waves 
utilising axial resolution. This maximises resolution. In B and C (representing the Apical 4 chamber view [A4C]) the US waves run parallel to the 
open leaflet in B (utilising lateral resolution) and although perpendicular to the closed MV leaflet in this view the valve is in the far-field which 
decreases resolution due to the spread of the US beam in the farfield. N – Nearfield, F – Farfield, MV – mitral valve, AMVL – anterior mitral valve 





FIGURE 4: Separating leaflet from chords.
The image on the left demonstrates good separation of leaflet from chordal tissue with the mitral valve in the closed position. This is significantly 
more difficult to achieve with the valve open (image on the right) where chords attaching to the ventricular surface of the valve end up “on top” 
of the anterior mitral valve leaflet (Arrow). In this position chords are often very difficult to separate from the leaflet and are included in the 
thickness measurement. An intermediate position might provide a good compromise of separation and resolution in these cases.
Modification of this methodology might be one strategy of 
bringing normal AMVL thickness measurements by echo-
cardiography (normal up to 3mm with harmonics off and 
possibly up to 4mm with harmonics on) more in line with 
leaflet thickness measurements quoted from pathology studies 
(around 1mm in the typical screening ages and up to 1.6mm in 
the older patient population).(16, 23, 24) The effect that ultra-
sound pulse length has on increasing apparent leaflet thick-
ness is unlikely to account for a three-fold increase in this 
measurement on fundamental imaging and if relevant could be 
accounted for by using a leading-edge-to-leading-edge measure-
ment convention.
When acquiring the PSLAX image, with a view to assessing 
leaflet thickness of the mitral valve, the sonographer should 


















attempt to section the most central portion of the AMVL 
rather than towards the commissures. A narrow central strip of 
the leaflet can often be identified that is relatively devoid of 
chordal tissue in the frame (Figure 7). Once the image is 
stopped and scrolled it is also useful to visually compare the 
basal aspect of the AMVL to the apparent thickness of the 
leaflet tip. If a uniform thickness can be seen to run through, 
from base to tip, it makes the presence of true thickening 
unlikely and aids the eye in separating leaflet from chord. The 
fact that RHD often affects the leaflet in a focal manner with 
the tips affected first, also presents the opportunity to do a 
relative leaflet thickness assessment, similar to that done for the 
assessment of aortic valve thickness. 
Posterior mitral valve leaflet (PMVL) tip thickening is recorded 
much less frequently in the patient cohort with asymptomatic 
RHD, but may be more specific and is not as easily “over read”. 
Sensitivities suffer if this is used in isolation though.
Leafl et restriction
Leaflet restriction, and specifically the pattern of leaflet restric-
tion, is arguably the most specific feature of “rheumatic 
morphology” quoted in the WHF criteria. The most common 
form of leaflet restriction in RHD is leaflet tip restriction due to 
commissural fusion (see explanation of mechanism below). This 
FIGURE 5: Chordal arrangement to the AMVL.
The AMVL in this gross pathology specimen shows the ventricular 
aspect of the mitral valve. Primary chords attach closer to the 
edge of the leaflet and secondary strut chords (white arrow) to 
the body of the leaflet. This adds significant bulk to the otherwise 
thin leaflet.
FIGURE 6: Apparent AMVL tip thickening.
These 2 parasternal long axis still frames of the mitral valve demonstrate apparent anterior mitral valve leaflet (AMVL) tip thickening (blue arrow) 
due to chordal interference left. Partially closing the MV solved the dilemma easily. The chordal overlap responsible for the thickening could then 
be identified as separate structures and eventually a separate and thin AMVL running through this (white arrow) was demonstrated with the valve 
almost completely closed (right).
FIGURE 7: Measuring leaflet thickness.
The central portion of the AMVL (blue strip) is relatively devoid 
of strut chords that add bulk to leaflet thickness measurements. 
The leaflet should be sectioned in this central portion to try and 





FIGURE 8: PSLAX sweep.
See text for full descriptive legend.
Side to side tilting 





FIGURE 9: Mechanism of bowing from commissural fusion: Mitral Valve.
Commissural fusion limits vertical leaflet edge separation in diastole (see red arrow above). If AMVL length remains unchanged, this must translate 
into bowing of the mobile leaflet body as seen in the PSLAX frames. The PSLAX images illustrate the fact that the leaflet tip motion is halted along 














PSLAX – Systolic and 
diastolic frames


















leads to diastolic bowing of the leaflet, identical to that seen in 
patients with Mitral stenosis (MS), but often to a lesser degree 
in the subclinical RHD population. Bowing of the AMVL is 
assessed primarily in the PSLAX. Freeze the PSLAX image 
optimised to show the AMVL and carefully scroll to show the 
AMVL when the leaflet reaches its maximal diastolic excursion. 
At this point bowing can be defined as the tip of the AMVL 
pointing posteriorly towards the posterior LV wall rather than 
parallel or away from this wall. Assessing the presence and 
distribution of bowing of the AMVL is a critical step in the 
evaluation of early restriction of a valve. As is often seen in 
more advanced disease with unilateral commissural fusion, and 
also in the post mitral valvuloplasty patient after unilateral 
commissural cleaving, the leaflet bowing is maximal on the side 
of maximal commissural fusion. Sweeping from commissure to 
commissure (tilting the echo probe from side to side in the 
PSLAX) is therefore an important manoeuvre to do since 
unilateral bowing of the leaflet may be prominent on one side 
of the valve only, ipsilateral to the fusion (Figure 8). It should 
be noted that bowing of the AMVL is also seen in congenital 
clefts of this leaflet and AV bowing is typical of bicuspid aortic 
valve disease, so that the presense of bowing should always 
spark a search for these pathologies. Unfortunately the com-
plexity does not stop here as it would appear that bowing of 
the medial aspect of the AMVL is also seen quite frequently in 
the normal population and must be differentiated from that 
associated with RHD. This also explains why bowing is often 
overcalled when evaluated in the apical 4 chamber view (and 
why this view should not be used to evaluate bowing) where 
the sonographer is evaluating the posteromedial aspect of 
the AMVL (A2/A3). The exact mechanism of this observation 
requires to be fully elucidated. More advanced leaflet restriction 
can be seen as a fixed leaflet, a configuration often seen of the 
PMVL in more advanced cases. It is informative to understand 
why bowing occurs in rheumatic valves, as it is such an important 
identifier of rheumatic valvular involvement (Figures 9 and 10). 
When acquiring the PSLAX, and scrolling from commissure to 
commissure, the sonographer should attempt to acquire the 
most central portion of the AMVL for assessment of evidence 
of rheumatic bowing. The relatively narrow central strip of 
the leaflet is identified as an area relatively devoid of chordal 
tissue. A judgment should also be made as to whether bowing 
appears to be isolated to the medial aspect of a valve other-
FIGURE 10: Bowing from Commissural fusion: Aortic valve (AV).
This top image row shows how normal AV opening occurs around a fulcrum with its two corners in the apexes of adjacent AV commissures (blue 
interrupted lines). Open commissures allow the free luminal edges of the 3 semilunar cusps (green lines) to end up almost  flush against the aortic 
wall in systole (orange lines). The bottom image row represent a rheumatic aortic valve with fusion of the basal half of each commissure. The 
fulcrum around which each semilunar cusp can now hinge (blue interrupted line) has been moved closer to the tip of each semilunar cusp and 
therefore towards the center of the aortic lumen because of the commissural fusion. This prevents the aortic leaflet edges (green) from ending 
up flush with the aortic wall at maximum systole. This leads to stenosis in severe cases, but also underpins the mechanism of bowing in less severe 
cases. Commissural fusion limits leaflet edge separation in systole and therefore limits the opening area of the AV in systole (green area). If AV 
leaflet length remains unchanged, this must translate into bowing of the mobile leaflet body as seen in a long axis view. The long axis (LAX) images 
illustrate the fact that the leaflet tip motion is halted along the normal arc of motion, but the body and or base continues to move forward leading 
to bowing. Bowing is a very telling sign of commissural fusion seen at any valve from whatever pathology. This AV description underlines the fact 











wise free of rheumatic features which, as stated before, is a 
frequently seen normal pattern.
A more subtle finding of leaflet restriction, often seen in the 
presence of bowing, is that the AMVL loses its free fluttering of 
the tips (ossilation around the horizontal when the leaflet is 
maximally open) as the AMVL leaflet becomes tethered to the 
PMVL in the commissures. Identifying this free fluttering tip 
motion is reassuring and argues against commissural fusion 
being present. The absence of fluttering should spark the search 
for leaflet tip bowing, more advanced forms of leaflet restriction 
and more direct evidence of commissural fusion.
FIGURE 12: The rheumatic mitral commissure.
Partial fusion at the apex of the postero-medial commissure (PMC) involving the lower edge of the commissural scallop and complete fusion at 
the apex of the antero-lateral commissure (ALC) is illustrated in the line drawing.  The leaflet angle running into the commissure often becomes 
more angulated once fusion occurs. This freeze-frame illustrates a lateral commissure that does not separate freely due to fusion seen right at the 
edge of the commissure. AMVL bowing was prominent in this case.




FIGURE 11: The normal mitral commissure.
The normal mitral commissure allows for free separation of the AMVL and the PMVL in the commissure. A commissural scallop often facilitates 
this separation. This normal “unhinging” of the AMVL and PMVL is critical for ensuring a large MV orifice in diastole. Commissural fusion causes 
fusion of the AMVL and PMVL edge in the commissure resulting in a reduced MV orifice opening area. Fluttering is a more subtle feature of the 
normal, freely mobile commissure.
Free AMVL and PMVL 
edge separation is seen 
in both the commissures.
























Commissural fusion is a very specific marker of rheumatic mitral 
valve involvement. It is well known to be the mechanism for the 
development of MS in advanced RHD. The normal mitral valve 
area is 4-6cm2 and it stands to reason that mild degrees of 
commissural fusion will initially reduce the mitral valve area only 
slightly, and not into the MS range. The specificity of this process 
is what makes it such an appealing marker of rheumatic valve 
involvement. As noted above, rheumatic bowing of the mitral 
and aortic valves lead to bowing through commissural fusion as 
the predominant mechanism, but commissural fusion should 
also be sought directly. Both commissures must be carefully 
inspected in the parasternal short axis view (PSSAX) for 
evidence of early fusion. The normal mitral valve is seen to 
allow free separation of the AMVL from the PMVL in the 
commissure. This is often fascilitated by a commissural scallop 
and allows for almost parallell separation of the 2 leaflets in the 
commissure. The PSSAX view must be modified, with an acqui-
sition done slightly more basally, to optimise the view of the 
commissures and in some cases the two commissures must be 
acquired using two separate views (angulated differently for 
each commissure) in order to optimise each commissure for 
assessment. Unfortunately, the learning curve for this assessment 
is quite steep and minor fusion can be difficult to visualise on 
2D echocardiography which significantly degrades the sensitivity 
of this technique as an isolated feature. In some cases, however, 
it simplifies an otherwise difficult assessment significantly 
(Figures 11, 12).
SUB VALVULAR INVOLVEMENT
The rate of identifiable sub valvular involvement in the 
asymptomatic RHD population appears to be quite low. It is 
important to screen both chordal systems carefully for areas of 
thickening. The most difficult area to assess is the area of chord 
just below the AMVL tips. It can be difficult to accurtely judge 
where the leaflet ends and the chords begin in the PSLAX 
view with the MV maximally open. Sidelobe artifact can cause 
“lateral smearing” of linear structures (such as the chords which 
will be running horizonatlly in the PSLAX view) which often 
make this assassment very difficult. For the same reasons 
chordal thickening is often over read in the PSLAX view and if 
suspected from this view, must be confirmed by apical scanning 
before calling it. The modified 4C, 2C and 3C views from the 
apex are very useful in assessing the whole length of the chords 
for areas of abnormal thickening.
EXCESSIVE LEAFLET TIP MOTION DURING 
SYSTOLE / LEAFLET TIP PROLAPSE (MV)
The central mechanism for the development of MR in RHD is 
so-called pseudo-prolapse. As suggested by this terminology 
there is no true prolapse at play here. Rather, the mechanism of 
MR in these cases is PMVL restriction which causes the AMVL 
tip to move past the relatively fixed PMVL during systole, 
leading to a coaptation defect and MR. True prolapse is rarely 
seen. It is accepted that chordal rupture, with subsequent 
prolapse or flail, rarely complicates acute rheumtic fever and 
excessive leaflet motion can, in these selected cases, be a cause 
for pathological MR. Excessive leaflet motion is, however, in our 
experience not a feature of rheumatic MR or AR outside of the 
acute rheumatic fever phase of the condition, and only rarely 
in this situation. The inclusion of excessive leaflet motion as 
defined by “excessive leaflet tip motion during systole/tip 
prolapse” conspires to achieve 2 things: Firstly, it risks inclusion 
of prolapse spectrum disease into the rheumatic popultion 
being screened and secondly it risks double scoring for true 
RHD cases with pseudo prolapse. In the latter cases the 
candidate will be scored for both “tip prolapse” and PMVL 
restriction which represents the same thing in these cases. 
Identifying PMVL restriction is an important component of 
identifying the mechanism of pseudo-prolapse seen in RHD. 
This mechanism should not be implied by focusing on tip 
movement without identifying the restriction component. The 
recurring theme of true rheumatic diastolic leaflet restriction 
appears to be a central ingredient in the diagnostic process 
towards asymptomatic RHD. Note: Similar arguments can be 
made for the aortic valve in terms of the “prolapse” criterium.
COAPTATION DEFECT OF THE AORTIC 
VALVE (AV)
Visualising a coaptation defect in AR is typically associated with 
significant AR, but is in no way specific for rheumatic involve-
ment. The inclusion of this criterion amongst the morphological 
critera of rheumatic AV involvement is interesting, but either 
inaccurate or out of place, belonging perhaps amongst mor-
phological markers of severity rather than suggesting it 
represents rheumatic AR specifically.
It is important that we are critical when looking at the criteria 
used to diagnose RHD so that we can improve on them and 
thus take the field forward. Some of the individual criteria of the 
WHF tasked with identifying pathological regurgitation appear 
to be redundant. Conversely, some of the criteria that form 
the basis of a morphological diagnosis of the condition appear 
to deviate from what we see in daily clinical practice. This will 
have to be reconciled if we wish to move forward with our 
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hope of large-scale population based screening. Weaknesses in 
the original WHO Doppler criteria has been perpetuated by 
“incorporation” of these criteria into the WHF criteria and 
the matter of form versus function, and where the focus 
should lie, still needs to be addressed. Further progress in 
development of the criteria must remain an important goal. 
This will necessitate ongoing and critical scrutiny of the criteria 
to understand where and why certain aspects are weak and 
where they could be improved upon. A deeper understanding 
of the mechanisms involved, and credible fundamentals under-
lying all proposed criteria, are paramount to rationalising and 
improving the criteria.
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